Loading stock data…
Addex Therapeutics Ltd discovers (ADXN)
$6.07+0.13 (+2.19%)
Pre-Market$5.81-0.26 (-4.22%)· Last close Jun 26
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Addex Therapeutics Ltd in the Healthcare sector is trading at $6.07 with a market capitalization of $8M. The stock is currently near its 52-week low of $5.41, remaining 20.9% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 15/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|
| Total Revenue | $248↓ | $29,724 | $0 | $0↓ | $1,508 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$779,263↓ | -$696,175↑ | -$732,898↓ | -$606,262↓ | -$445,626 |
| Net Income | -$1.84M↓ | -$1.58M↑ | -$1.84M↓ | -$1.47M↓ | -$1.21M |
Peer Comparison
JNJUNHPFE
Fundamentals
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs includ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.86M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-141.15%
Volume
Today's trading volume
11,119
Recent News
Addex Therapeutics Ltd (ADXN) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...
Despite financial hurdles, Addex Therapeutics Ltd (ADXN) makes significant strides in drug development and strategic positioning.
Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Highlights: Strategic Advances Amidst ...
Despite stable financials, Addex Therapeutics Ltd (ADXN) focuses on promising R&D progress and strategic partnerships to drive future growth.
Addex Therapeutics Ltd (ADXN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ...
Despite a decrease in income and rising liabilities, Addex Therapeutics Ltd (ADXN) makes significant strides in drug development and strategic partnerships.
European Market Insights: Addex Therapeutics Among 3 Promising Penny Stocks
The European stock market has shown resilience, with the pan-European STOXX Europe 600 Index rising amid expectations of a potential rate cut by the U.S. Federal Reserve. As investors navigate these shifting economic landscapes, penny stocks emerge as an intriguing area of focus, offering opportunities in smaller or newer companies at lower price points. Despite being considered a throwback term, penny stocks can still represent valuable investment prospects when backed by strong financials...